- Home
- JNVR vs EDSA Comparison
JNVR vs EDSA Comparison
Compare JNVR & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- EDSA
- Stock Information
- Founded
- JNVR 2018
- EDSA 2015
- Country
- JNVR United States
- EDSA Canada
- Employees
- JNVR N/A
- EDSA N/A
- Industry
- JNVR Finance: Consumer Services
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- JNVR Finance
- EDSA Health Care
- Exchange
- JNVR Nasdaq
- EDSA Nasdaq
- Market Cap
- JNVR 5.4M
- EDSA 6.2M
- IPO Year
- JNVR 2023
- EDSA N/A
- Fundamental
- Price
- JNVR $5.29
- EDSA $2.35
- Analyst Decision
- JNVR
- EDSA Strong Buy
- Analyst Count
- JNVR 0
- EDSA 1
- Target Price
- JNVR N/A
- EDSA $21.00
- AVG Volume (30 Days)
- JNVR 16.2K
- EDSA 31.4K
- Earning Date
- JNVR 03-13-2025
- EDSA 05-09-2025
- Dividend Yield
- JNVR N/A
- EDSA N/A
- EPS Growth
- JNVR N/A
- EDSA N/A
- EPS
- JNVR N/A
- EDSA N/A
- Revenue
- JNVR $2,099,660.00
- EDSA N/A
- Revenue This Year
- JNVR N/A
- EDSA N/A
- Revenue Next Year
- JNVR N/A
- EDSA N/A
- P/E Ratio
- JNVR N/A
- EDSA N/A
- Revenue Growth
- JNVR 4.82
- EDSA N/A
- 52 Week Low
- JNVR $3.37
- EDSA $1.55
- 52 Week High
- JNVR $10.64
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- JNVR 59.29
- EDSA 50.89
- Support Level
- JNVR $4.45
- EDSA $2.37
- Resistance Level
- JNVR $6.42
- EDSA $2.55
- Average True Range (ATR)
- JNVR 0.67
- EDSA 0.11
- MACD
- JNVR 0.12
- EDSA -0.01
- Stochastic Oscillator
- JNVR 58.78
- EDSA 25.93
About JNVR Janover Inc.
Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from transaction fees.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.